Protocols · Metabolism/Weight Loss
Sema Weight Management Protocol
GLP-1 Receptor Agonist | Weight Management & Metabolic Health
Typical Dose
0.125–2.4 mg weekly
Titrated from microdose start to therapeutic ceiling over 20+ weeks
Route
Subcutaneous
Abdomen, thigh, or upper arm; rotate sites weekly
Cycle
9–12 months active + taper
Titration → maintenance → 12–16 week structured taper
Storage
Refrigerate 2–8°C
Stable at room temp up to 28 days post-reconstitution per compounding guidance
Patient version available. Share ?view=patient with patients for the plain-language handout.
Overview
Sema (a GLP-1 receptor agonist) remains a cornerstone pharmacologic tool for clinically significant weight reduction in patients with BMI ≥30, or ≥27 with weight-related comorbidities (T2DM, HTN, dyslipidemia, OSA, MASLD). The protocol below frames a structured titration-maintenance-discontinuation strategy designed to maximize fat mass loss while mitigating GI intolerance, lean mass loss, and post-discontinuation weight regain.
The target patient is a metabolically dysregulated adult who has failed structured lifestyle intervention, is appropriately screened for contraindications, and is committed to concurrent nutritional, resistance training, and behavioral support. Two compounded strengths (15 mg and 30 mg vials) provide flexible titration from microdose initiation through full therapeutic range, allowing the clinician to tailor escalation to tolerance rather than the rigid manufacturer schedule.
The protocol's clinical goal is 12–18% total body weight loss over 9–12 months with preservation of lean mass, followed by a deliberate taper or maintenance phase to consolidate metabolic adaptations and reduce rebound hyperphagia.
Key Benefits
12–18% total body weight loss achievable over 9–12 months at therapeutic dose, with concurrent improvements in glycemic control, lipids, blood pressure, and food noise. Strong cardiovascular outcome data in patients with overweight/obesity and established CVD.
Mechanism of Action
Long-acting GLP-1 receptor agonist activating hypothalamic satiety centers, delaying gastric emptying, augmenting glucose-dependent insulin secretion, and modulating mesolimbic food reward pathways.
Molecular Information
Weight
4113.58 Da
Length
31 amino acids
Type
GLP-1 analog with C18 fatty acid side chain
Amino Acid Sequence
HAibEGTFTSDVSSYLEGQAAK(γE-C18 diacid)EFIAWLVRGRG
* Aib = α-aminoisobutyric acid (position 2, confers DPP-4 resistance). Fatty acid conjugation at Lys26 enables albumin binding.
Pharmacokinetics
Research Indications
Chronic Weight ManagementMOST EFFECTIVE
BMI ≥30
First-line pharmacotherapy after failed lifestyle intervention
BMI ≥27 with comorbidity
T2DM, HTN, dyslipidemia, OSA, MASLD
Mean TBWL
~14.9% at 68 weeks per STEP program (2.4 mg weekly)
Type 2 DiabetesMOST EFFECTIVE
HbA1c reduction
0.5–1.2% reduction in dysglycemic patients at 12 weeks
Glucose-dependent action
Insulinotropic effect without hypoglycemia risk in non-diabetics
Cardiovascular Risk ReductionEFFECTIVE
MACE reduction
SELECT trial demonstrated CV event reduction in overweight/obese patients with established CVD
Lipid & BP improvement
Measurable reductions in triglycerides and systolic BP by week 8
MASLD / Hepatic SteatosisEMERGING
Hepatic fat reduction
Weight-loss-mediated improvement in hepatic steatosis and transaminases
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Initiation (Weeks 1–2) | 0.125 mg | Weekly | SC |
| Early titration (Weeks 3–4) | 0.25 mg | Weekly | SC |
| Low titration (Weeks 5–8) | 0.5 mg | Weekly | SC |
| Mid titration (Weeks 9–12) | 1.0 mg | Weekly | SC |
| High titration (Weeks 13–20) | 1.5–2.0 mg | Weekly | SC |
| Therapeutic ceiling (Weeks 21+) | 2.4 mg | Weekly | SC |
| Maintenance (stable patients) | Lowest effective dose | Every 7–14 days | SC |
| Taper (12–16 weeks) | Reduce ~25% q4 weeks | Weekly | SC |
Timing · Inject same day each week, with or without food. If a dose is missed and the next dose is >2 days away, take ASAP; otherwise skip and resume schedule. Slow titration improves tolerability over the manufacturer label.
Peptide Interactions
- Tirzepatide— Do not stack GLP-1 with dual GIP/GLP-1 agonist — overlapping mechanism, additive GI toxicityAVOID
- Retatrutide— Overlapping GLP-1 mechanism — switch, do not combineAVOID
- Insulin / Sulfonylureas— Hypoglycemia risk; reduce dose 20–50% at initiationMONITOR
- BPC-157— May mitigate GI side effects during titrationSYNERGISTIC
- CJC-1295 / Ipamorelin— GH axis support may help preserve lean mass during weight lossCOMPATIBLE
- Tesamorelin— Complementary visceral fat reduction; lean mass preservationSYNERGISTIC
- AOD-9604— Adjunctive lipolytic; no known PK interactionCOMPATIBLE
- Levothyroxine— Delayed gastric emptying may alter absorption — recheck TSH at 8–12 weeksMONITOR
- Oral contraceptives— Counsel on backup contraception during titrationMONITOR
How to Reconstitute
- 1
Wash hands and disinfect work surface; gather vial, bacteriostatic water, syringes, and alcohol swabs
- 2
Allow lyophilized Sema vial to reach room temperature (~15 minutes)
- 3
Swab both vial stoppers (Sema and BAC water) with fresh alcohol pads
- 4
For 15 mg vial: draw 1.5 mL BAC water (yields 10 mg/mL). For 30 mg vial: draw 3.0 mL BAC water (yields 10 mg/mL)
- 5
Inject diluent slowly down the inner wall of the Sema vial — do not jet directly onto powder
- 6
Do not shake. Gently swirl or roll the vial until fully clear (1–2 minutes)
- 7
Inspect solution: should be clear and colorless with no particulates
- 8
Label vial with reconstitution date and concentration
- 9
Draw weekly dose: at 10 mg/mL, 0.125 mg = 1.25 units, 0.25 mg = 2.5 units, 1.0 mg = 10 units on a U-100 insulin syringe
- 10
Inject SC into abdomen, thigh, or upper arm; rotate sites weekly
- 11
Store reconstituted vial refrigerated 2–8°C; use within 28 days
- 12
Discard if cloudy, discolored, or past 28 days
Quality Indicators
Clear, colorless solution
Properly reconstituted Sema should be optically clear with no precipitate or color
Steady weekly weight loss
0.5–1.5% TBWL per week during active titration is typical
Persistent severe nausea
Hold escalation 2–4 weeks or drop to prior tolerated dose
Rapid lean mass loss
Reinforce protein 1.2–1.6 g/kg IBW and resistance training
Cloudy or particulate solution
Do not inject — discard and re-reconstitute from fresh vial
<5% TBWL at 12 weeks on ≥1.0 mg
Hypo-responder pattern; reassess adherence, nutrition, sleep, thyroid, or switch agent
What to Expect
Week 1–4: Reduced appetite and food noise; GI side effects often peak in this window
Week 4: 2–4% TBWL, smaller portion sizes, early satiety
Week 8: 5–7% TBWL, measurable improvements in fasting glucose, triglycerides, and BP
Week 12: 8–10% TBWL in responders; HbA1c reductions of 0.5–1.2% in dysglycemic patients
Week 24–36: 12–18% TBWL achievable at therapeutic dose in adherent patients
Month 9–12: Plateau commonly emerges; transition to maintenance dosing strategy
Lean mass loss of 25–40% of total weight lost is common without resistance training
Post-discontinuation: rebound hyperphagia and weight regain are well-documented without structured taper
Side Effects & Safety
- Nausea, early satiety, eructation (titration-phase, dose-dependent)
- Constipation or diarrhea
- Fatigue and transient hair shedding (often nutritional)
- Injection site reactions
- Gallstones / cholecystitis with rapid weight loss
- Lean mass loss without resistance training and adequate protein
- Sulfur-like eructation (less common)
When to Stop & Call Provider
- Severe persistent abdominal pain radiating to back (rule out pancreatitis)
- Severe RUQ pain, fever, or jaundice (gallbladder workup)
- Persistent vomiting or signs of gastroparesis
- Allergic reaction or hypersensitivity symptoms
- Pregnancy or planned conception within 2 months
- Neck mass, dysphagia, or persistent hoarseness (thyroid workup)
References
STEP 1: Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding et al., NEJM 2021. Mean TBWL of 14.9% at 68 weeks with semaglutide 2.4 mg weekly vs 2.4% placebo, with concurrent improvements in cardiometabolic risk factors.
STEP 4: Effect of Continued Weekly Semaglutide vs Placebo on Weight Loss Maintenance
Rubino et al., JAMA 2021. Demonstrated significant weight regain after semaglutide discontinuation, supporting need for continued therapy or structured taper for weight loss maintenance.
SELECT: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff et al., NEJM 2023. 20% reduction in composite MACE endpoint in patients with established CVD and overweight/obesity, independent of diabetes status.
STEP 5: Two-Year Efficacy and Safety of Semaglutide for Weight Management
Garvey et al., Nature Medicine 2022. Sustained 15.2% TBWL at 2 years, confirming durability of weight loss with continued therapy at 2.4 mg weekly.